FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

PALO ALTO, Calif.--(BUSINESS WIRE)--May 23, 2024--

Related Keywords

Massachusetts ,United States ,California ,Canada ,Vancouver ,British Columbia ,American ,Americans ,Amirali Talasaz ,Mike Weist ,Daniel Chung ,Zarak Khurshid ,Devices Advisory Committee ,Facebook ,Guardant Health ,American College Of Gastroenterology ,Their Association ,Exchange Commission ,American Cancer Society ,Nasdaq ,Guardant Health Inc ,Linkedin ,Professor Of Medicine At Harvard Medical School ,Clinical Genetics Panel ,National Colorectal Cancer Roundtable ,Drug Administration ,Medical Devices Advisory Committee ,Massachusetts General Hospital ,Harvard Medical ,New England Journal ,Guardant Blood Collection ,Financial Condition ,Annual Report ,Key Statistics ,Survival Rates ,Colorectal Cancer ,Accessed May ,Blood Based Colorectal Cancer Screening ,Real World Clinical ,Scientific Meeting ,American College ,Colorectal Cancer Screening ,Randomized Clinical Trial ,March Intern ,Colorectal Cancer Screening Process ,Investor Contact ,Business Wire ,